11beta-[4-(Dimethylamino)phenyl]-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
84371-65-3CC#C[C@]1(O)CCC2C3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21CVKHAHZOOUSRJNA-YYTJNDDGSA-NSee also: Mifepristone (annotation moved to).
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
用途ミフェプリストン (mifepristone) は、抗グルココルチコイド作用と抗アンドロゲン作用も持つ薬物。通常、ミソプロストールとの併用により使用される。妊娠7週(49日;受精からは5週間相当)以内の初期であれば胎児は膣から血塊となって排出され中絶される。
説明Mifepristone is an orally-active progesterone and glucocorticoid receptor antagonist indicated for use as a post-coital contraceptive. In addition to being an abortifacient, mifepristone is reported to be effective in the treatment of ocular hypertension; its potential therapeutic effect in hormone-dependent tumors is currently under investigation.
来歴Mifepristone (brand name: Mifeprex) is an abortion drug approved by the FDA in 2000 for the medical termination of pregnancy, up to 7 weeks of gestation, an extension extended to 10 weeks in 2016. A generic version of Mifeprex, mifepristone tablets (200 mg), was approved in 2019. The drug has been in use for 25 years. However, following a study by the Center for Ethics and Public Policy (EPPC) showing that nearly 11% of women using the drug experience serious adverse events, the FDA is reviewing the safety of mifepristone.
使用Mifepristone is a progesterone receptor antagonist with partial agonist activity. Abortifacient.
現在のフィルター条件では反応記録がありません。
読み込み中…
84371-65-3化学的特性Pale Yellow Solid